Related Experiment Video

Updated: Jan 16, 2026

Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.8K

Exploring the Potential of Nuciferine in Diabetes Management via PTGS2 Pathway Targeting by Network Analysis and in

N Sridevi1, Thirumal Margesan1

  • 1Department of Pharmacognosy, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, 603203, Chengalpattu, Tamil Nadu, India.

Current Medicinal Chemistry
|October 1, 2025
PubMed
Abstract

Insights

This study identifies Nuciferine as a potential natural compound to combat type 2 diabetes. It targets PTGS2 (prostaglandin-endoperoxide synthase 2), a key enzyme in diabetic inflammation and insulin resistance.

Area of Science:

  • Computational chemistry and pharmacology
  • Biomedical research
  • Drug discovery

Background:

  • Diabetes mellitus is a global health issue, with insulin resistance and chronic inflammation central to type 2 diabetes.
  • PTGS2 (prostaglandin-endoperoxide synthase 2) is implicated in inflammatory pathways relevant to diabetic complications.

Purpose of the Study:

  • To identify natural compounds with potential anti-diabetic activity using computational methods.
  • To investigate the role of PTGS2 in diabetes-related inflammation and insulin resistance.

Main Methods:

  • Employed network pharmacology to map compound-target-pathway relationships.
  • Utilized in silico molecular docking to assess the binding affinity of phytochemicals with PTGS2.
  • Analyzed PTGS2 association with diabetic inflammation and insulin resistance.

Main Results:

  • Nuciferine and Corytuberine showed high binding affinity to PTGS2.
  • Network pharmacology confirmed Nuciferine's link to PTGS2, indicating its potential as a therapeutic agent.
  • PTGS2 and its pathways are strongly linked to diabetic inflammation and insulin resistance.

Conclusions:

  • PTGS2 plays a role in the progression of insulin resistance and inflammation in type 2 diabetes.
  • Nuciferine shows promise for modulating PTGS2 activity and improving insulin sensitivity.
  • Further in vivo and clinical studies are necessary to validate Nuciferine's therapeutic potential for diabetes.
Keywords:
Cissampelos pareiraPTGS2Terminalia belliricainsulin resistancemolecular dockingnetwork pharmacology.

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

922

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594